Stocks
Investment Opportunities in Techno Drugs Considering Financial Viability
Techno Drugs Limited’s private company primarily focuses on specialized products, offering a range of products in Oncology, Anesthesia, Birth Control Pills, Injections, and modern technology Implant sticks (for 5-year birth control). The company was registered as a private company in 2009 and converted into a public company in 2019. Additionally providing veterinary and general human medicines.
Their main medicines include:
Birth Control Medicines: Sukhi 3rd Generation oral pill, Provera Injection, Implant Stick 5 years birth control
Anti-cancer Medicines: Hertin, Zolomide, Eposide
Anesthesia Medicines: Lidocaine plus Inj, Vencuron-10 IV Inj
General Human Medicines: Motilex Suspension, Omsec, Romilac, Cefixon Injection.
Veterinary Medicines: Vermic Inj, Dexavet Inj, Rumen plus pow, Vitazinc Sol
Techno Drugs Limited has been advancing in producing and distributing high-quality medicines. The company’s management director, Mehereen Ahmed, holds a PhD in Oncology from Dhaka University, ensuring expertise in the field. The management team and staff work diligently to ensure quality.
Every year, Techno Drugs Limited supplies the highest amount of birth control medicines in opposition to tenders from the Family Planning Directorate of the Bangladesh Government. With 17 depots across the country, they ensure nationwide distribution. The company also has a “24/7 Monitoring Team” at every level to ensure proper monitoring of all company operations.
With listing on the stock market, Techno Drugs Limited anticipates increased production and sales, benefiting investors and stockholders. Their commitment to corporate governance, job creation, business expansion through IPO funds, and regular dividends to investors aims at socio-economic development in the country and enhancing the country’s reputation in the global pharmaceutical market.
Techno Drugs continues to produce life-saving medicines and is progressing as a profitable company. With various specialized products and a wide range of human and veterinary medicines, they aim for further advancement in the future. Currently, the company’s total capital is approximately 94 crores taka with management holding 63% and the management board having 88% of the shares. Techno Drugs believes that with their capable management and dedicated staff, they will achieve more success in the future, making it a secure investment for investors.
Dhaka Stock Market DSE, Bourse on the second working day of the week, 30th September, ended with a negative performance in Indices and a hike in Turnover from the previous working session. This information is known from DSE sources.
503 crore 90 lakh taka shares were traded on this day. 22 crore 58 lakh more tradings were done in DSE today compared to the previous workday, 29th September, Shares worth Tk 481 crores 31 lakh shares were traded last time, Sunday.
The benchmark DSEX lost 33.61 points or 5,624 The Shariah-based index DSES dropped 7.36 point or 1,263 and the blue-chip index DS30 decreased by 9.57 points or 2,053.
Of the issues traded, 72 advanced, 299 declined and 25 remained unchanged.
Shahjibazar Power Company Limited ranked top gainer on DSE, the share price increased by Tk 4.00 paisa or 9.76 percent. On this day, the share was last traded at Tk 45.00 paisa.
Dhaka Electric Supply Company Limited ranked top loser on the DSE, the share price dropped by Tk 1.80 paisa or 7.56 percent. On this day, the share was last traded at Tk 22.00 paisa.
DSE topped on trade is Pragati Life Insurance Limited 25 crore 35 lakh takas of company shares have been traded.
A total of 27 companies’ shares were traded in the Block on Dhaka Stock Exchange. A total of 1 crore 50 lakh 42 thousand 956 shares of the companies were traded. The financial value of which is 65 crore 60 lakh taka
One of the Listed companies, National Polymer Limited has recommended 10.50% Cash Dividend for the year ended June 30, 2024.
It has reported Consolidated EPS of Tk 2.27 paisa, and Consolidated NAV per share of Tk 30.63 for the year ended March 31, 2024.
The Annual General Meeting (AGM) of the company will be held on December 18, through the digital platform. The record date for this has been fixed at October 22.
The Company also discloses its financial reports for the second quarter, (April – June 24).
As per the company’s consolidated life revenue account for April to June 2024, the excess of total income over total expenses, including claims (surplus), stood at Tk 1,394.24 million. This marks a significant increase from the surplus of Tk 823.68 million during the same period in 2023.
For the first half of 2024, from January to June, the company reported a surplus of Tk 2,177.57 million, compared to Tk 1,290.39 million in the corresponding period of the previous year.
Additionally, the Life Insurance Fund balance as of June 30, 2024, reached Tk 55,188.62 million, showing a net increase of Tk 5,892.25 million from Tk 49,296.37 million on June 30, 2023.
One of the Listed companies, Beacon Pharmaceuticals PLC has recommended 20% Cash dividend and 10% Cash Dividend to Sponsor Shareholder and Directors for the year ended June 30, 2024.
It has reported EPS of Tk 2.26 paisa, and NAV per share of Tk. 26.37 for the year ended June 30, 2024.
The Annual General Meeting (AGM) of the company will be held on December 23, through the digital platform. The record date for this has been fixed at October 27.
